


# S1P Pathway Mutations Associate with Disease Stage in DLBCL

Retention pathway effect strongest in GCB (Schmitz); Egress pathway effect in pan-DLBCL (Duke); DFCI underpowered


## A. Schmitz 2018: GCB-DLBCL

EZB subtype (GNA13/RHOA-enriched) | n=80



## B. Duke 2017: Pan-DLBCL


All COO subtypes | n=974



## C. DFCI 2018: GCB-DLBCL


Sample-level mutations | n=21

OR=0.80, p=1.00  
(underpowered)



## D. Odds Ratios for Late-Stage Disease

Reference: No pathway mutation / Non-EZB



Retention pathway: GNA13, RHOA, S1PR2, P2RY8, ARHGEF1 | Egress pathway: GNAI2, CXCR4, S1PR1  
EZB genetic subtype used as proxy for retention pathway mutations (Schmitz). Filled circles = p<0.05; Open circles = NS